Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / RUNX3

RUNX3

Basics

Aliases:
This biomarker is also known as:
  • CBFA3,
  • SL3-3 enhancer factor 1 alpha C subunit,
  • PEBP2-alpha C,
  • PEBP2A3,
  • Runt-related transcription factor 3,
  • SL3/AKV core-binding factor alpha C subunit,
  • Oncogene AML-2,
  • AML2,
  • Acute myeloid leukemia 2 protein,
  • CBF-alpha-3,
  • PEA2-alpha C,
  • Core-binding factor subunit alpha-3,
  • Polyomavirus enhancer-binding protein 2 alpha C subunit,

Description…

RUNX3 is a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene.

Attributes

QA State: Accepted
Type: Genomic
Short Name:
HGNC Name: RUNX3

Organs

The following organs have data associated with this biomarker…

Esophagus

Attributes

Phase: Two
QA State: Accepted

Overview

Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.

Performance Comment

p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.

Supporting Study Data

The following studies/protocols provide evidence supporting RUNX3 indications for the Esophagus…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Lung

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Supporting Study Data

The following studies/protocols provide evidence supporting RUNX3 indications for the Lung…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

No organ-specific publications defined.

Organ-Specific Resources

No organ-specific resources defined.

Studies

No associated studies or protocols found.

Biomuta

Mutation Statistics

Gene Name: RUNX3
UniProt Accession #: Q13761
Mutated Sites Count: 113
Associated Pubmed ID Count 9
CancerDO Count 21
Affected Protein Function Sites Count: 4

View in BioMuta